Biotech AI for UK genome study

2015-09-30 21:13

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Chicago - Berg, a private company that uses artificial intelligence to discover new drugs and diagnostics, will help England's national genomics project mine DNA and health data from thousands of British citizens for potential drug targets.

Berg, based in Boston, was co-founded in 2006 by Silicon Valley real estate billionaire Carl Berg. Since then, it has been working to change the way drugs are discovered, working in partnership with key players such as the US Department of Defense and the Parkinson's Institute Clinical Center.

Its newest agreement is with the Genomics England 100 000 Genomes Project, which aims to accelerate development of new diagnostics and treatments through a year-long industry trial, company executives told Reuters.

The project focuses on patients with rare diseases and six common cancers. Industry partners include drugmakers such as Roche, Biogen, AstraZeneca and GlaxoSmithKline.

Berg uses artificial intelligence "to look at patterns in the data to find areas in the biology that are fingerprints of that disease," Niven Narain, Berg's co-founder and president, said in an interview. It plans to open a UK office in the next year to shepherd the project and seek new collaborations with drug company and academic partners in Europe.

Leading biotech companies are collecting genomic information on hundreds of thousands of patients to search for new drug leads.

Berg says its approach allows it to add far more data points in addition to DNA. The company uses its artificial intelligence supercomputer platform - known to insiders as 'Betsy' - to look at what is going on inside cells, studying all the proteins, the lipids that form cell membranes and govern cell communication and the way cells metabolize energy.

Since last April, it has worked with Beth Israel Deaconess Medical Center and the Pancreatic Cancer Research Team to hunt for leads on pancreatic cancer by analysing blood samples from nearly 1 900 patients.

"The Berg approach essentially does away with the assumption that genes, by themselves, are responsible for disease or the absence of it," said Dr James Moser of Beth Israel Deaconess.

Berg is also planning Phase 2 trials in early 2016 for its experimental cancer drug called BPM 31510 aimed at treating solid tumours, Narain said. The treatment works by reversing changes in the metabolism of cancer cells that allow them to thrive.

The drug was based on predictions from the computer model, which helped the company choose how to develop the drug. Early-stage data suggests the drug helps shrink tumours when used alone, and increases the potency of chemotherapy when used in combination.

"We're seeing responses in gastric cancer, oesophageal cancer, pancreatic cancer, liver cancer, renal cell sarcomas" - all highly metabolic tumours, Narain said.

Read more on:    uk  |  health  |  research  |  dna

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

Inside News24


Book flights

Compare, Book, Fly

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.